Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ionis Earns $5M Biogen Milestone | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

Ionis Earns $5M Biogen Milestone

Validates neurological disease target

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Ionis Pharmaceuticals, Inc. has earned a $5 million milestone payment from Biogen associated with the validation of an undisclosed neurological disease target. The companies have a broad strategic collaboration focused on leveraging antisense technology to develop drugs to treat patients with neurological disorders. For this newest target, Ionis will continue to evaluate the target with the goal of advancing this program into development. 
 
“The recent FDA approval of SPINRAZA highlights the potential of our antisense technology to address neurological diseases with high unmet need,” said B. Lynne Parshall, chief operating officer at Ionis. “This latest milestone is one more example of the success of our strategic collaboration with Biogen. Under this collaboration, we have advanced SPINRAZA to commercialization and another four drugs into development. We have also validated four more targets with drug candidates that we are advancing toward development. This work has generated a combined total of approximately $555 million to date. As we enter 2017, we expect to continue to make significant progress in growing our neurological disease pipeline.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics